Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02445911 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of KQ-791 in Diabetes Mellitus
A Phase 1 study of Diabetes Mellitus, Type 2, sponsored by Kaneq Bioscience Limited.
- Completed
- Registry status
- Phase 1
- Development phase
- 81
- Enrollment target
- 4
- Study locations
NCT02445911: Completed Phase 1 study of Diabetes Mellitus, Type 2, sponsored by Kaneq Bioscience Limited.
NCT02445911 is a Phase 1 study of Diabetes Mellitus, Type 2 that has completed, run by Kaneq Bioscience Limited. The registered enrollment target is 81 participants, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (98% lower). The trial reports 4 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02445911, a Phase 1 study of Diabetes Mellitus, Type 2, has completed, sponsored by Kaneq Bioscience Limited.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 81 participants
- Enrollment target
- 4
- Study locations
Study Summary
This study will consist of multiple ascending oral doses in up to 3 groups, for 29 days.
Primary Outcome
Data table is change from baseline in Fasting Blood Glucose. Statistical Analysis includes results for difference in Change from baseline in Fasting Blood Glucose Between KQ-791 and Placebo.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG KQ-791
Study Locations (4)
Florida
- Clinical Pharmacology of Miami, Inc. - Miami
- Orlando Clinical Research Center - Orlando
Arizona
- Celerion - Tempe
Nebraska
- Celerion - Lincoln
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 81 participants |
| Start Date | 2015-06 |
| Est. Completion | 2016-02 |
| Phase | Phase 1 |
What the finished NCT02445911 record still lists
NCT02445911 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 81 participants, a relatively small participant target, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Diabetes Mellitus, Type 2 appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02445911 reports a single indexed study location in Florida, Arizona, Nebraska.
Frequently Asked Questions
What is clinical trial NCT02445911 about?
NCT02445911 is a clinical study titled "Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of KQ-791 in Diabetes Mellitus". This study will consist of multiple ascending oral doses in up to 3 groups, for 29 days.
What is the current status of trial NCT02445911?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 81 participants. The study started on 2015-06. Estimated completion is 2016-02.
What conditions does trial NCT02445911 study?
This clinical trial studies the following conditions: Diabetes Mellitus, Type 2.
What interventions are being tested in trial NCT02445911?
The interventions under investigation include: Placebo (DRUG), KQ-791 (DRUG).
Who is sponsoring clinical trial NCT02445911?
This trial is sponsored by Kaneq Bioscience Limited, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02445911 being conducted?
This trial has 4 study locations across Arizona, Florida, Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus, Type 2
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02445911's enrollment target sits among peer trials
81 216th of 348 higher than 133 of 348 other Diabetes Mellitus, Type 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetes Mellitus, Type 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Clinical Trial of MK-1403 in Participants With Type 2 Diabetes Mellitus (MK-1403-006)
RECRUITING · Phase 1
-
Multiple Dose Study of MK-2828 in Participants With Type 2 Diabetes (MK-2828-003)
RECRUITING · Phase 1
-
Study to Understand the Genetics of the Acute Response to Metformin and Glipizide in Humans
ACTIVE NOT RECRUITING · Phase 1
-
Study of Subcutaneously Administered ENT-03 for the Treatment of Obesity and Diabetes
ACTIVE NOT RECRUITING · Phase 1
-
A Family Dyad-focused Diabetes Self-Management Intervention for African American Adults
ACTIVE NOT RECRUITING · Phase 1
-
Multiple Dose Safety Toelrability, Pharmacokinetics and Midazolam Interaction In Healthy Overweight And Obese Subjects
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04966481 · 81 participants · Phase 3
Palbociclib and Cetuximab Versus Cetuximab Monotherapy for Patients With CDKN2A-altered, HPV-unrelated Head and Neck Squamous Cell Carcinoma Who Experienced Disease Progression on a PD-1/L1 Inhibitor
- NCT05109429 · 81 participants · NA
Developing a Clinical Outcome Assessment for Opioid Craving
- NCT05112601 · 81 participants · Phase 2
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
- NCT05305911 · 81 participants · Phase 2
Sodium Glucose Co-Transporter 2 (SGLT2) and STEMI
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia